These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1491 related articles for article (PubMed ID: 26457538)

  • 1. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
    Yu OH; Yin H; Azoulay L
    Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of DPP-4 inhibitors on cardiovascular outcomes in patients with type 2 diabetes and end-stage renal disease.
    Chan SY; Ou SM; Chen YT; Shih CJ
    Int J Cardiol; 2016 Sep; 218():170-175. PubMed ID: 27236110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
    Ou HT; Chang KC; Li CY; Wu JS
    Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
    Jil M; Rajnikant M; Richard D; Iskandar I
    Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PURLs: Need an add-on to metformin? Consider this.
    Wyncott D; Lyon C; Mounsey A
    J Fam Pract; 2017 Jan; 66(1):42-44. PubMed ID: 28188318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
    Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.